Pan-cancer Proteogenomics Expands the Landscape of Therapeutic Targets

We integrate Clinical Proteomic Tumor Analysis Consortium (CPTAC) pan-cancer dataset with other public datasets to provide insights into existing cancer drug targets and to systematically identify candidate new targets for drug repurposing or development. The analyses include overexpressed and hyperactivated protein dependencies, protein dependencies associated with the loss of tumor suppressor genes, and putative neoantigens and tumor-associated antigens. Detailed method description and results can be found in the accompanying Cell publication.

Gene Pharos Family Target Tier Drug Antigen Score

*Drug font weight coding: Approved oncology drug; Approved non-oncology drug; Investigational drug. TSA: Tumor-specific antigen; TAA: Tumor-associated antigen. Score: Number of significant analysis results.